AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Sign up Log in

ELIXINOL WELLNESS LIMITED Call Transcript 2019

Feb 26, 2019

64891_rns_2019-02-26_b583b349-139f-4d16-b6f0-8ea7b0f7b67b.pdf

Call Transcript

Open in viewer

Opens in your device viewer

==> picture [115 x 81] intentionally omitted <==

ASX Announcement: 27 February 2019

ELIXINOL GLOBAL LIMITED FY2018 FULL YEAR RESULTS PRESENTATION CONFERENCE CALL RECORDING

Elixinol Global Limited ( EXL or the Group ) (ASX:EXL; OTCQX:ELLXF) , a global company operating in the industrial hemp and emerging medicinal cannabis sectors, is pleased to provide an audio recording of the FY2018 full year results presentation conference call, held by EXL’s Chief Executive Officer, Paul Benhaim and Chief Financial Officer, Ron Dufficy on Tuesday 26 February 2019.

The recording is available on the Elixinol Global website via the following link: https://www.elixinolglobal.com/site/media-centre/media-gallery/audio-and-video.

Investor relations and media please contact:

Australia United States of America Glen Zurcher Cody Slach Account Director, IR Department Managing Director, Liolios Group Inc [email protected] [email protected] +61 420 249 299 +1 949 574 3860

About Elixinol Global

Elixinol Global Limited (ASX:EXL; OTCQX:ELLXF) through its businesses has a global presence in the cannabis industry including hemp-derived CBD dietary supplements, hemp food and wellness products, as well as cultivation and manufacture of medicinal cannabis products. EXL’s businesses include:

Elixinol LLC (“Elixinol”), founded in 2014, is a manufacturer and global distributor of hemp dietary supplement and skincare products, with operations based out of Colorado, USA.
Hemp Foods Australia Pty Ltd (“Hemp Foods Australia”), founded in 1999, is a leading hemp food wholesaler, retailer, manufacturer and exporter of bulk and branded raw materials, and finished products.
Nunyara Pharma Pty Ltd (“Nunyara”), formerly known as Elixinol Australia, was founded in 2014 to participate in the emerging Australian medicinal cannabis market and submitted licence applications for cultivation and manufacture to the Office of Drug Control in early 2018. These applications are currently pending approval.